

Colorectal Cancer Drugs and Companies in Asia-Pacific Markets to 2023

Colorectal Cancer Therapeutic in Asia-Pacific Markets to 2023

PUNE, INDIA, August 3, 2017 /EINPresswire.com/ -- Pune, India, 3rd August 2017: WiseGuyReports announced addition of new report, titled "[Colorectal Cancer](#) Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market".

Summary

Colorectal Cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.4 million newly diagnosed CRC cases in 2012, accounting for 9.7% of the total number of cancer cases. This figure has been gradually rising in the Asia-Pacific region, with the growing elderly population and increasingly Westernized lifestyles.

CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/1685720-colorectal-cancer-therapeutics-in-asia-pacific-markets-to-2023-launch-of> □

The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations.

The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies. In the current market, RAS-wild-type and RAS-mutant patients can be treated with angiogenesis inhibitors such as Avastin, Cyramza and Zaltrap, while patients with RAS- or KRAS-wild-type mutations can be prescribed EGFR-targeted therapies such as Erbitux and Vectibix. However, significant unmet need remains for products that can treat BRAF-mutant CRC patients. A therapy that targets mutant BRAF - encorafenib plus binimetinib - is being developed in the pipeline.

Scope

The CRC Asia-Pacific market will be valued at \$7.9 billion in 2023, growing from \$4.7 billion in 2016 at a CAGR of 7.9%.

- How will immune checkpoint inhibitors such as Keytruda and Tecentriq contribute to growth?
- What effect will patent expirations of currently branded therapies have on market value?

The CRC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies.

- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
- What implications will the increased focus on targeted therapies have on the future of CRC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

- How have the late-stage therapies performed in clinical trials?
- How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

- How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
- How could changes in risk factors such as population age, obesity and lifestyle influence the market?

Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under \$10m to over \$3 billion.

- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as

the individual contributions of promising late-stage molecules to market growth.

- Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.

Table of Content: Key Points

1 Table of Contents	5
1.1 List of Tables	8
1.2 List of Figures	8
2 Introduction	10
2.1 Disease Introduction	10
2.2 Epidemiology	10
2.3 Symptoms	12
2.4 Etiology and Pathophysiology	12
2.5 Diagnosis	15
2.6 Disease Stages	17
2.7 Prognosis	19
2.8 Treatment Guidelines and Options	20
3 Marketed Products	26
3.1 Overview	26
3.2 Chemotherapies	26
3.3 Epidermal Growth Factor Receptor Targeted Therapies	29
3.4 Anti-angiogenesis Therapies	33
...Continued	

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/1685720-colorectal-cancer-therapeutics-in-asia-pacific-markets-to-2023-launch-of> □

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports> □

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/396041725>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.